Carillion PLC
20 November 2003
20 November 2003
Carillion sells PPP equity and announces increased dividend
Carillion has agreed to sell its equity interest in the Darent Valley Hospital
PPP concession to Barclays UK Infrastructure Fund, an existing shareholder in
the project, for a cash consideration of £5.2 million.
In addition to the £5.2 million that Carillion expects to receive for its equity
interest, the sale will crystallise as profit the £11.2 million of cash received
when this PPP concession was refinanced in March 2003. Carillion's proceeds
from the sale and refinancing are therefore some £16.4 million, four times the
value of the original investment in this project of £4.1 million.
The sale is expected to generate a net exceptional profit of around £11 million,
after taking account of profits already consolidated since equity was invested
in this project. The Board intends to return to shareholders one third of this
exceptional profit, by way of a dividend, equating to approximately 1.7 pence
per ordinary share. This additional element of dividend will be added to the
normal ordinary dividend for the full year ending 31 December 2003. It is the
Board's current intention to return a proportion of the proceeds from future PPP
equity sales to shareholders.
In accordance with HM Treasury Guidelines, the refinancing gain was shared with
the Dartford and Gravesham NHS Trust, which received some £10 million mainly in
the form of lower annual payments to the Special Purpose Vehicle company.
Carillion will continue to provide non-clinical facilities management services
at Darent Valley Hospital where it has a 32-year contract, which started in
2000.
The sale is in line with Carillion's previously announced intention to sell PPP
equity investments in order to demonstrate their value and to support the
Group's ongoing commitment to investing in further PPP projects. The value
achieved by the sale supports the company's valuation of the Group's PPP
investment portfolio in March 2003, of around £115 million.
Commenting, Carillion Chief Executive, John McDonough, said: 'This sale meets
all the objectives we set when we announced our intention to recycle our PPP
equity investments. It demonstrates their value to shareholders and generates
funds to support the Group's increasing investment in new PPP projects which
will provide further returns for shareholders.
'We expect interest in the secondary market for PPP equity to remain positive
and intend to continue recycling PPP equity through new sales in 2004 and
beyond.'
Due to the sale of its equity interest in Darent Valley Hospital, the level of
pre-tax profit that Carillion will report in its Investments segment will reduce
by around £1 million in 2004.
The sale is expected to be completed within a week, subject to confirmation from
the Credit Rating Agency, Moody's Investors Service, that its credit rating for
the public bond used to provide debt finance for this project will remain
unchanged. Standard & Poor's have already confirmed that their rating will
remain unchanged under the agreed terms of the sale.
Notes to editors
Details of Carillion's portfolio of financially closed projects are set out in
the table below.
PFI/PPP Project Financial Status Concession Carillion Carillion FM & Maint
Close Period (yrs) Equity Equity (% Value to
Date Invested to share) Carillion
date (£m)
Roads
M40 Motorway 1997 Operational 30 13.2
50.0 175.0
A55 North Wales 1998 Operational 27 5.9
50.0 -
Other Transport
Notts Express Transit (NET) 2000 In Construction 30 3.4
12.5 -
Hospitals/Healthcare
Darent Valley Hospital 1997 Operational 32 4.1
30.0 158.0
Glasgow Southern General 1999 Operational 27 0.6
50.0 35.0
The Great Western Hospital, 1999 Operational 27 4.6
Swindon 33.3 168.0
Harplands Hospital 1999 Operational 29 1.1
50.0 44.0
Secure accommodation
HMP Altcourse 1995 Operational 25 -
50.0 8.0
Medway Secure Training Centre 1997 Operational 15 0.3
50.0 1.0
Rainsbrook Secure Training 1998 Operational 15 0.4
Centre 50.0 -
HMP Rye Hill 1999 Operational 25 0.5
50.0 5.0
Manchester Magistrates Court 2001 In Construction 25 -
33.3 -
Other accommodation
University of Greenwich 1995 Operational 30 - 100.0
-
New Accommodation Project 2000 Operational 30 9.0
(GCHQ) 40.0 49.0
University of Hertfordshire 2002 Operational 32 3.3
50.0 55.0
In addition to its financially closed projects, Carillion is the preferred
bidder for seven new PPP projects worth some £2.5 billion and is also
shortlisted for six projects worth around £1.6 billion. The seven projects at
preferred bidder stage include the John Radcliffe Hospital, Oxford; the Queen
Alexandra Hospital, Portsmouth; the William Osler Hospital, Ontario, Canada; The
Royal Ottawa Hospital, Ontario, Canada; Birmingham and Solihull LIFT; the A249
road project in Kent and a social housing project in Derbyshire.
For further information contact
John Denning, Director Group Corporate Affairs - 01902 316384
Paula Manning, Corporate Communications Manager - 01902 316444
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.